Ovizio raises €8m from NSV et al.

The round featured capital from Belgian funds Qbic and Theodorus III, Louvain-headquartered VC Nausicaa Ventures and a group of private investors including Pierre Drion.

The fresh capital will finance Ovizio's plans to bolster its R&D team via 15 new hires, five of whom are expected for 2015. The business will look to improve its technology and add new products to its current offering.

The company is looking to capitalise on a growing cell-counting market, foreseen to represent €7.56bn in business by 2020. According to the company's figures, the broader in-vitro diagnostics segment, a priority for the business in the upcoming years, will hit the €66bn mark by 2020, driven by ageing demographics and the prevalence of chronic conditions.

According to unquote" data, the round represents NSV's second foray in the Belgian healthcare sector in recent months. In September, the New York-headquartered VC headed a group of investors backing a €28m series-A for regenerative tissue developer Novadip Biosciences.

In addition, the investment is the second in a week to involve Nausicaa, a VC that writes €1-4m tickets for Belgian early-stage businesses. Recently, the firm took part in a $10.2m series-B for customer intelligence software developer NGData led by Idinvest.

Company
Founded in December 2009, Ovizio develops microscopes equipped with real-time 3D and 4D cell-imaging technologies. Created as a spin-off of Université Libre de Bruxelles, the company is headquartered in Brussels, where a new office and R&D laboratory were opened in March 2015.

People
NSV was represented by managing partner Somu Subramaniam. Philip Mathuis co-founded Ovizio and is currently CEO of the business.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Expansion
• Healthcare
• Belgium